

There is an urgent need to develop robust pharmacovigilance systems for antiretrovirals particularly in resource-limited settings. This detailed manual gives a step by step approach to undertaking the pharmacovigilance of these medicines. Good pharmacovigilance will identify the risks in the shortest possible time after the medicine has been marketed and will help to identify risk factors. This manual describes the principles of both spontaneous reporting systems and cohort event monitoring programmes. It is intended to be a source of practical advice for Pharmacovigilance Centres and health professionals involved in HIV/AIDS programmes.

Following the success of the manual, which was first published in 2009, this new edition includes revised questionnaires and guidance documents, making it an even more valuable resource for all who are involved in the development of pharmacovigilance systems for antiretrovirals.

ISBN 978 92 4 154794 9



A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF ANTIRETROVIRAL MEDICINES

A PRACTICAL HANDBOOK ON THE PHARMACOVIGILANCE OF ANTIRETROVIRAL MEDICINES



A practical
handbook on the
pharmacovigilance
of antiretroviral
medicines



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data:

A practical handbook on the pharmacovigilance of antiretroviral medicines.

1. Drug monitoring.
 2. Drug utilization review – methods.
 3. Anti-retroviral agents – adverse effects.
 4. Adverse drug reaction reporting systems.
 5. Handbooks.
- I. World Health Organization.

ISBN 978 92 4 154794 9

(NLM classification: QV 771)

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by minimum graphics

Printed in France

Contents

Abbreviations	xi
Acknowledgements	xiii
A. Introduction	1
1. Pharmacovigilance	1
1.1 Definition	1
1.2 Explanation	2
1.3 General aims	2
1.4 Specific aims	3
1.5 Pharmacovigilance of antiretrovirals	3
2. Pharmacovigilance centre	4
B. Passive or active pharmacovigilance?	5
1. Passive pharmacovigilance	5
2. Active pharmacovigilance	5
C. Spontaneous reporting	6
1. Introduction	6
1.1 Background	6
1.2 Adverse reactions	6
2. Objectives	6
2.1 The purpose of spontaneous reporting	6
2.2 Background to the methodology	7
2.3 Serious reactions	8
3. Minimum reporting requirements	9
3.1 WHO criteria	9
3.2 Other practical conditions	9
4. How to report	9
4.1 Reporting form	9
4.2 Other options for reporting	10
5. Where to report	10

6. What to report	11
6.1 Essential data elements	11
6.2 Advice to reporters	12
6.3 Follow-up when necessary	13
7. When to report	13
8. Who should report	13
9. Sharing the results	14
9.1 Individual, immediate	14
9.2 Relevant summaries or reviews	14
9.3 Regular transmission to the WHO database	14
10. Data entry	15
10.1 Options	15
10.2 VigiFlow	15
D. Cohort Event Monitoring	16
1. Introduction	16
1.1 Event monitoring	16
1.2 Description	16
1.3 Objectives	17
1.4 Selection of drugs to monitor	17
1.5 Basic processes	18
1.6 Programme duration	18
2. Epidemiology	19
2.1 Observational	19
2.2 Prospective	19
2.3 Inceptional	19
2.4 Dynamic	19
2.5 Longitudinal	19
2.6 Descriptive	20
3. First step – Implementation	20
3.1 First action	20
3.2 Pilot exercise	20
3.3 Sites and training	20
3.4 Advocacy	20
3.5 Reasons for monitoring	21
3.6 Approaches to advocacy	21

4. Second step – establishing the cohort(s)	22
4.1 Numbers of patients	24
4.2 Selection of patients	24
4.3 Patient identification	24
4.4 Other patient data	25
4.5 Background data	25
4.6 Controls or comparators	25
5. Third step – acquiring the data	26
The medicines	26
5.1 Details of administration of ARVs	26
5.2 Concomitant medicines	27
The events	28
5.3 Principles of event reporting	28
5.4 What kind of events?	28
5.5 Recording event details	29
5.6 Reporting forms (questionnaires)	29
5.7 Logistics of data recording	31
5.8 Frequency and duration of monitoring	33
5.9 Reasons for lack of adherence	35
5.10 How and where to send the completed questionnaires	35
5.11 Record linkage	36
6. Database for CEM	36
6.1 Choice of database	36
6.2 Data elements/fields	37
7. Maximizing the reporting rate	39
7.1 Prepare the ground	39
7.2 Removing barriers to reporting.	39
7.3 Other health facilities	40
7.4 Feedback	40
8. General advice and information	40
8.1 Don't ask for too much	40
8.2 Non-serious events	40
8.3 Be open-minded	41
8.4 Privacy	41
9. Fourth step – Clinical review	41
9.1 The event should be specific to be acceptable for recording	41

9.2	Determining the event term	42
9.3	The events dictionary	42
9.4	Dictionary maintenance	44
9.5	Seriousness	44
9.6	Severity	44
9.7	Outcome of the event	45
9.8	Relationship to the medicine/regimen	45
E. Data processing		46
1.	Data entry	46
1.1	Requirements	46
1.2	Standard formats	46
2.	Quality control	47
2.1	Control at entry	47
2.2	Systematic checks	47
3.	Coding of medicines and diseases	47
3.1	WHO Drug Dictionary	47
3.2	ICD-10	47
3.3	Standardized recording of event details	47
4.	Using CemFlow	48
5.	Collating and summarizing the events	48
F. Special types of event		50
1.	Serious events	50
2.	Pregnancies	50
2.1	Background	50
2.2	CEM of pregnancy	51
2.3	Pregnancy register	52
2.4	Expectations from CEM monitoring of pregnancies	52
2.5	Verification of drug-effect	53
2.6	WHO pregnancy registry	53
3.	Lactation exposure	54
4.	Deaths	54
5.	Lack of efficacy	55
5.1	Event terms	55
5.2	Reasons for lack of efficacy	55
6.	Late onset reactions	56

7. Concomitant morbid conditions 56

G. Relationship/Causality assessment 57

1. Background 57

1.1 Two basic questions 57

1.2 Objective and subjective assessments 57

1.3 General understanding 57

2. Factors to consider when assessing the relationship between drug and event 58

2.1 Did the event begin before the patient commenced the medicine? 58

2.2 Is there any other possible cause for the event? 58

2.3 Is the duration to onset of the event plausible? 58

2.4 Did the event occur after the commencement of some other medicine? 59

2.5 Did the event occur after the onset of some new illness? 59

2.6 What is the response to withdrawal of the medicine (dechallenge)? 59

2.7 What is the response to rechallenge? 59

3. Categories of relationship 60

4. Requirements for inclusion of an event in a specific category 60

4.1 Certain 60

4.2 Probable 61

4.3 Possible 61

4.4 Unlikely 62

4.5 Unclassified or conditional 62

4.6 Unassessable 62

5. Processes for establishing the relationship 63

5.1 Result of dechallenge 63

5.2 Result of rechallenge with the same medicine by itself 63

5.3 Outcome of the event 63

预览已结束，完整报告链接和工

<https://www.yunbaogao.cn/report/index/report?re>